Diclofenac Sodium Solution
FDA Recall NDC 62332-487

FDA Enforcement Report: View Recall Date, Reasons, and Safety Status

Active & Historical Enforcement Reports

The FDA has identified 1 recorded enforcement report(s) associated with Diclofenac Sodium (NDC 62332-487). A significant event, classified as Class II, was initiated on Jun 22, 2023 by Alembic Pharmaceuticals Inc.. The reported reason for this action was: "Defective Delivery System"

This recall is currently ONGOING. Healthcare providers and patients are advised to check their inventory immediately against the affected codes provided below.

Reported Recall Events

June 2023 Class II Recall: Defective Delivery System

Recall Number
Class II Ongoing
Reason for Recall
Defective Delivery System
Initiated
Jun 22, 2023
Reported
Aug 02, 2023
Quantity
2844 units

Recall Profile & Regulatory Data

Event ID
92581
Classification
Class II
Enforcement Status
Ongoing
Recalling Firm
ALEMBIC PHARMACEUTICALS, INC.
Voluntary / Mandated
Voluntary: Firm initiated
Distribution Pattern
Nationwide within the United States
Product Description
Diclofenac Sodium Topical Solution USP, 2% w/w, 3.8 FL.OZ.(112 grams) bottles, Rx only, Manufactured for: Alembic Pharmaceuticals, Inc. Bedminster, NJ 07921, USA Manufactured by: Alembic Pharmaceuticals Limited (Derma Division) Karakhadi, Vadodara 391450, India. NDC 62332-487-12
Batch or Lot Expiration Information
Lot# : 220151, 220152, 220153, Exp. Date 11/2024
Affected Packages Involved in this Recall
62332-487-12Product

About FDA Recall Enforcement Reports

FDA recall data documents classified recall actions associated with a product. Most recalls are limited to specific lots, batches, or package configurations rather than every unit of a drug.

If a recall is listed for an NDC, review the affected lot information and package details carefully. Patients and healthcare professionals should confirm whether a specific product in hand matches the lot or package information before assuming it is affected.